Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

First-in-class targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma

ecancermedicalscience editor's choice for May 2015

Virtual learning environment as a tool to provide laboratory training for hematology registrars

Analysis of iron status in paediatric acute lymphoblastic leukaemia

New approaches to diffuse large B-cell lymphoma

Latest in novel approaches to CLL and MCL

New T cell–based immunotherapy shows promise for lethal stem cell transplant complication

Putting the patient at the centre of cancer-associated thrombosis treatment decisions

Dual mTOR inhibition effective in reducing tumour load in CLL

Positive results in phase II study of copanlisib treating NHL and CLL

Updated results on phase III CLL trial shows 90% response rate using ibrutinib